Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valder R Arruda

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
JCI Insight|October 14, 2016
Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia modelsJoshua I Siner, Benjamin J Samelson-Jones, Julie M Crudele, et al.
Transfusion|January 9, 2007
A prospective study on the prevalence and risk factors for neonatal thrombocytopenia and platelet alloimmunization among 9332 unselected Brazilian newbornsVagner Castro, Hartmut Kroll, Andréa F Origa, et al.
Molecular Therapy. Methods & Clinical Development|December 14, 2023
Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dogLucas Van Gorder, Bhavya S Doshi, Elinor Willis, et al.
Blood|September 30, 2010
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapyJonathan D Finn, Margareth C Ozelo, Denise E Sabatino, et al.
Blood|July 5, 2007
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liverFederico Mingozzi, Nicole C Hasbrouck, Etiena Basner-Tschakarjan, et al.
American Journal of Hematology|September 25, 2004
Genetic variability of platelet glycoprotein Ibalpha geneMargareth C Ozelo, Devanira S P Costa, Lucia H Siqueira, et al.
Blood|September 21, 2010
In vivo efficacy of platelet-delivered, high specific activity factor VIII variantsTeshell K Greene, Cheng Wang, Jessica D Hirsch, et al.
Nature Biotechnology|October 25, 2011
A zymogen-like factor Xa variant corrects the coagulation defect in hemophiliaLacramioara Ivanciu, Raffaella Toso, Paris Margaritis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2010
Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogsVirginia Haurigot, Federico Mingozzi, George Buchlis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Safety and Efficacy of Regional Intravenous (RI) Versus Intramuscular (IM) Delivery of rAAV1 and rAAV8 to Nonhuman Primate Skeletal MuscleAlice Toromanoff, Yan Chérel, Mickaël Guilbaud, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
JCI Insight|October 14, 2016
Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia modelsJoshua I Siner, Benjamin J Samelson-Jones, Julie M Crudele, et al.
Transfusion|January 9, 2007
A prospective study on the prevalence and risk factors for neonatal thrombocytopenia and platelet alloimmunization among 9332 unselected Brazilian newbornsVagner Castro, Hartmut Kroll, Andréa F Origa, et al.
Molecular Therapy. Methods & Clinical Development|December 14, 2023
Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dogLucas Van Gorder, Bhavya S Doshi, Elinor Willis, et al.
Blood|September 30, 2010
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapyJonathan D Finn, Margareth C Ozelo, Denise E Sabatino, et al.
Blood|July 5, 2007
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liverFederico Mingozzi, Nicole C Hasbrouck, Etiena Basner-Tschakarjan, et al.
American Journal of Hematology|September 25, 2004
Genetic variability of platelet glycoprotein Ibalpha geneMargareth C Ozelo, Devanira S P Costa, Lucia H Siqueira, et al.
Blood|September 21, 2010
In vivo efficacy of platelet-delivered, high specific activity factor VIII variantsTeshell K Greene, Cheng Wang, Jessica D Hirsch, et al.
Nature Biotechnology|October 25, 2011
A zymogen-like factor Xa variant corrects the coagulation defect in hemophiliaLacramioara Ivanciu, Raffaella Toso, Paris Margaritis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 29, 2010
Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogsVirginia Haurigot, Federico Mingozzi, George Buchlis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Safety and Efficacy of Regional Intravenous (RI) Versus Intramuscular (IM) Delivery of rAAV1 and rAAV8 to Nonhuman Primate Skeletal MuscleAlice Toromanoff, Yan Chérel, Mickaël Guilbaud, et al.
Pageof 9